GlassScriptPhysician profile
Gregory W Roloff
NPI 1841795929
$29,175.70
in general payments reported to CMS, 2019-2025
8 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $114 · 2023: $2,238 · 2024: $3,286 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Honoraria: $7,030 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,982 · Travel and Lodging: $2,410 · Food and Beverage: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,030.00 |
| Honoraria | $7,030.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,982.33 |
| Travel and Lodging | $2,410.10 |
| Food and Beverage | $1,608.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $12,975.05 | 2023-2025 | Yescarta, Tecartus |
| Autolus INC | $10,478.49 | 2025 | |
| Rigel Pharmaceuticals, INC. | $3,788.75 | 2025 | Rezlidhia |
| Adaptive Biotechnologies Corporation | $973.71 | 2024 | Clonoseq |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Celgene Corporation | $133.38 | 2023 | |
| Incyte Corporation | $114.40 | 2022 | |
| Pfizer INC. | $61.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Roloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.